According to Alnylam Pharmaceuticals 's latest financial reports the company's current revenue (TTM ) is HK$25.10 Billion. In 2024 the company made a revenue of HK$17.45 Billion an increase over the revenue in the year 2023 that were of HK$14.27 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.